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Objective: We investigated whether use of HRT and duration of
use was associated with risk of development of asthma in
perimenopausal and postmenopausal women.
Methods: We constructed a 17-year (from January 1, 2000, to
December 31, 2016) open cohort of 353,173 women (aged 46-70
years) from the Optimum Patient Care Database, a longitudinal
primary care database from across the United Kingdom. HRT
use, subtypes, and duration of use; confounding variables; and
asthma onset were defined by using the Read Clinical
Classification System. We fitted multilevel Cox regression
models to estimate hazard ratios (HRs) with 95% CIs.
Results: During the 17-year follow-up (1,340,423 person years),
7,614 new asthma cases occurred, giving an incidence rate of 5.7
(95% CI 5 5.5-5.8) per 1,000 person years. Compared with
nonuse of HRT, previous use of any (HR 5 0.83; 95% CI 5
0.76-0.88), estrogen-only (HR 5 0.89; 95% CI 5 0.84-0.95), or
combined estrogen and progestogen (HR 5 0.82; 95% CI 5
0.76-0.88) HRT was associated with a reduced risk of asthma
onset. This was also the case with current use of any (HR 5
0.79; 95% CI 5 0.74-0.85), estrogen-only (HR 5 0.80; 95%
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https://doi.org/10.1016/j.jaci.2020.11.024(HR 5 0.78; 95% CI 5 0.70-0.87) HRT. Longer duration of
HRTuse (1-2 years [HR 5 0.93; 95% CI 5 0.87-0.99]; 3-4 years
[HR 5 0.77; 95% CI 5 0.70-0.84]; and >_5 years [HR 5 0.71;
95% CI 5 0.64-0.78]) was associated with a dose-response
reduced risk of asthma onset.
Conclusion: We found that HRT was associated with a reduced
risk of development of late onset asthma in menopausal
women. Further cohort studies are needed to confirm these
findings. (J Allergy Clin Immunol 2020;nnn:nnn-nnn.)
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Sex steroid hormones are believed to contribute to the observed
notable sex-related differences in the development and clinical
manifestation of asthma.1 Over several decades, several epidemi-
ologic studies have investigated the role of both endogenous and
exogenous sex steroids in the development of asthma in women,
but the underlying evidence remains uncertain. In our recent sys-
tematic review, most previous studies (which were predominantly
cross-sectional) showed that ever-use and current use of hormone
replacement therapy (HRT), compared with nonuse, were associ-
ated with an increased risk of development of asthma in meno-
pausal women.1 In contrast, some studies showed that HRT use
led to improved lung function in postmenopausal women.2,3 Pre-
vious studies have also shown that obesity and cigarette smoking
may modify the association between HRT and asthma.4,5
The cross-sectional design of most previous studies impedes
clear evaluation of any potential causal association between the
use of HRT and asthma. Additionally, ascertainment of HRT and
asthma, based on self-report (as was the case in the majority of
studies), highlights the importance of recall and information bias
in influencing the reported findings.6 In the light of these impor-
tant methodologic shortcomings, the role of HRT in the develop-
ment of asthma in menopausal women remains unclear. In
particular, there is a need to undertake more robust longitudinal
studies that will help clarify the underlying evidence base. In
the current study, we investigated the association of HRT use,
its subtypes, and duration of use with the risk of development
of asthma in menopausal women. We also examined whether
these associations were modified by body mass index (BMI)
and cigarette smoking.METHODS
Ethics approvals and permissions
This study was approved by the Anonymized Data Ethics and Protocol
Transparency Committee (reference no. ADEPT1317), which grants project-
specific approvals for use of data from the the Optimum Patient Care Research
Database (OPCRD). Optimum Patient Care has an existing National Health1
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2 SHAH ET ALAbbreviations usedBMI: Body mass indexER: Estrogen receptorGP: General practitionerHRT: Hormonal replacement therapyIMD: Index of Multiple DeprivationOPCRD: Optimum Patient Care Research DatabaseQOF: Quality and Outcomes FrameworkFIG 1. Direct acyclic graph showing the association between use of HRT
and asthma onset in females, with effect modification by BMI and smoking.Service Health Research Authority ethics approval for use of the OPCRD for
research (NHS Research Ethics Committee reference no. 15/EM/150). All
researchers involved in the data analysis completed required information
governance courses before working on the data.Protocol registration and publication
The study protocol was registered with the European Union Electronic
Register of Post-Authorization Studies (EUPAS22967). In addition, the
protocol was peer-reviewed and published before the analyses were
undertaken.7Study design and population
The study data were derived from OPCRD, which is a bespoke, longitu-
dinal, de-identified primary care database from across the United Kingdom
that is used to conduct epidemiologic, pharmaceutical, and clinical studies
(https://opcrd.co.uk/).8,9 At the time of this study, the OPCRD consisted of
data from 630 primary care practices that represented more than 6.5 million
patients. All individuals resident in the United Kingdom (including children)
are registered with primary care. We constructed an open retrospective cohort
of perimenopausal and postmenopausal women (aged 45-70 years) from the
database. Participants were followed from baseline (starting from January 1,
2000), the date of their registration to a general practice, or the year in which
they reached the age of 45 years until December 31, 2016. Exit date was
defined as the date of the first record of an asthma event, death, deregistration
from a practice, the year of in which the participant reached the age of 70
years, or the end of follow-up (December 31, 2016), whichever came first. Par-
ticipants without asthma at baseline or 5 years before the baseline date were
included and followed up. In total, 353,173 women met the inclusion criteria.Ascertainment and definition of study exposures
Using the Read Clinical Classification System (for the Read codes, see
Supplement 1 in the Online Repository at www.jacionline.org),10 we defined
the following exposures: (1) previous (anytime in the past) and current (during
that study year) use of any HRT versus nonuse; (2) previous and current use of
subtypes of HRT (estrogen-only or combined estrogen and progestogen)
versus nonuse; (3) duration of HRT use (treated as a persistent variable) of
1 to 2 years, 3 to 4 years, and 5 years or more versus nonuse; and (4) meno-
pausal status of perimenopausal (age 46-55 years) versus postmenopausal
(age 56-70 years). HRTusewas counted only if it occurred before the outcome
and was ascertained for each year of follow-up.Potential confounding variables
A directed acyclic graph was used to select potential confounding factors
adjusted in our analysis (Fig 1). Confounding factors were extracted by using the
relevant Read codes (see Supplement 2 in the Online Repository at www.
jacionline.org) and included age, gravidity, BMI, smoking, Charlson Comorbid-
ity Index score,11 any gynecologic condition (endometriosis, polycystic ovary
syndrome, acne, bilateral salpingo-oophorectomy, hysterectomy bilateral
salpingo-oophorectomy, hysterectomy, fibroids, or menstrual bleeding com-
plaints identified under the coding terms menorrhagia, metrorrhagia, and meno-
metrorrhagia),12 and Index of Multiple Deprivation (IMD) quintile.13Outcome
Asthma onset was defined as the first ever general practitioner (GP)-
recorded asthma event defined by using the primary care codes associatedwith
asthma diagnosis occurring any time after the baseline date. To ensure that
only patients who did not have asthma at the start of the follow-up were
included in the cohort, a broader definition of asthma (defined as occurrence of
either asthma diagnosis or asthma-related hospitalization, exacerbation, or
medication prescription) was used to exclude patients who may have asthma
before the baseline date. The relevant Read codes are provided in Supplement
3 (in the Online Repository at www.jacionline.org).Statistical analyses
We used the Pearson chi-square test and differences in means to describe
the distribution of the baseline study characteristics, use of HRT, and incidence
of asthma.We used extendedKaplan-Meier curves14 to describe survival func-
tions (for additional details regarding the risk of remaining asthma-free, see
Supplement 6 in the Online Repository at www.jacionline.org) by HRT cate-
gories (type and duration). Multilevel mixed-effects extended Cox regression
was used to study the association of HRT use and menopausal status with risk
of asthma onset. This allowed us to account for the time-varying nature of
exposure and confounders, as well as for the clustering of patients from the
same practice. Adjusted analyses included all of the aforementioned factors.
To evaluate any potential for residual confounding, we calculated the
E-values15 for the observed estimates of association of HRT use and meno-
pausal status with asthma onset. We included interaction terms for smoking
and BMI in each adjusted model to evaluate the interactions between HRT
use and these factors in relation to asthma onset. Models in which interaction
term achieved a P value less than .20 were stratified for BMI or smoking. Data
management and editing were undertaken by using R software, version 3.5.1
(R Foundation for Statistical Computing, Vienna, Austria). Statistical analyses
were undertaken using Stata 14 software (Stata Statistical Software, release 14
[StataCorp LP, College Station, Tex]).Reporting
This article has been written following the recommendations of STROBE
(Strengthening the Reporting of Observational Studies in Epidemiology)16
and RECORD (Reporting of studies Conducted Using Observational
Routinely Collected Data).17RESULTS
Baseline characteristics of the study populations
Table I and Fig 2 provide the baseline characteristics of the
population. Of the 353,173 women at risk of asthma who were
included in the study, 16% used any HRT, 9% used combined es-
trogen and progestogen HRT, and 7% used estrogen-only HRT at






(n 5 57,104 [16%]),
% (95% CI)*
Used estrogen 1 pro-
gestogen combined HRT
(n 5 31,281 [9%]),
% (95% CI)*
Used estrogen-only HRT
(n 5 25,823 [7%]),
% (95% CI)*
Asthma incidence during
follow-up (n 5 7,614),
incidence rate per 1000
person years (95% CI)
Age (y)
46-50 114,544 (32.4) 10.6 (10.4-10.7) 5.7 (5.6-5.8) 4.9 (4.7-5.0) 5.00 (4.83-5.17)
51-55 71,582 (20.3) 24.1 (23.8-24.5) 14.9 (14.6-15.1) 9.2 (9.0-9.5) 6.09 (5.81-6.38)
56-60 61,055 (17.3) 23.5 (23.1-23.8) 13.3 (13.0-13.6) 10.2 (9.9-10.4) 6.30 (5.97-6.65)
61-65 54,043 (15.3) 15.8 (15.5-16.1) 7.4 (7.2-7.6) 8.3 (8.1-8.6) 6.65 (6.23-7.11)





193,816 (54.9) 16.3 (16.2-16.5) 9.6 (9.5-9.7) 6.7 (6.6-6.8) 5.61 (5.44-5.80)
Postmenopausal (age
56-70 y)
159,357 (45.1) 16.0 (15.8-16.1) 7.9 (7.8-8.1) 8.0 (7.9-8.1) 5.74 (5.57-5.93)
Smoking status, no. (%)
Nonsmoker 175,235 (49.6) 14.6 (14.4-14.8) 7.7 (7.6-7.8) 6.9 (6.8-7.0) 5.05 (4.88-5.22)
Ex-smoker or current
smoker
177,938 (50.4) 17.7 (17.5-17.9) 10.0 (9.9-10.1) 7.7 (7.6-7.8) 6.28 (6.09-6.47)
BMI, kg/m2
<25 139,415 (39.5) 17.6 (17.4-17.8) 10.3 (10.1-10.4) 7.3 (7.2-7.5) 4.12 (3.94-4.30)
25-29.9 121,825 (34.5) 17.0 (16.8-17.2) 9.2 (9.0-9.3) 7.9 (7.7-8.0) 5.58 (5.37-5.80)
>_30 91,933 (26.0) 12.8 (12.5-13.0) 6.3 (6.1-6.4) 6.5 (6.4-6.7) 7.85 (7.57-8.14)
Gravidity, no. (%)
None 241,719 (68.4) 16.9 (16.7-17.0) 9.2 (9.1-9.3) 7.7 (7.6-7.8) 6.17 (6.00-6.34)
1 40,811 (11.6) 14.9 (14.6-15.3) 8.5 (8.2-8.7) 6.4 (6.2-6.7) 5.00 (4.68-5.33)
2 41,096 (11.6) 15.0 (14.7-15.3) 8.4 (8.1-8.6) 6.6 (6.4-6.9) 4.86 (4.56-5.17)
>_3 29,547 (8.4) 13.5 (13.1-13.9) 7.3 (7.0-7.6) 6.2 (5.9-6.5) 4.90 (4.55-5.27)
Any gynecologic
condition
No 251,959 (71.3) 14.9 (14.7-15.0) 10.0 (9.9-10.1) 4.9 (4.8-5.0) 6.02 (5.79-6.26)
Yes 101,214 (28.7) 19.4 (19.1-19.6) 6.0 (5.9-6.1) 13.4 (13.1-13.6) 5.53 (5.38-5.68)
Charlson Comorbidity
Index, no. (%)
0 303,205 (85.8) 16.5 (16.4-16.6) 9.2 (9.1-9.3) 7.3 (7.2-7.4) 5.58 (5.44-5.72)
1-3 11,129 (3.2) 11.6 (11.0-12.2) 5.5 (5.1-6.0) 6.0 (5.6-6.5) 5.58 (4.94-6.30)
>_4 38,839 (11.0) 14.7 (14.3-15.0) 7.2 (7.0-7.5) 7.5 (7.2-7.7) 6.22 (5.89-6.57)
IMD quintile, no. (%)
First quintile (least
deprived)
82,551 (23.4) 14.4 (14.1-14.6) 8.0 (7.8-8.2) 6.4 (6.2-6.5) 6.42 (6.14-6.71)
Second quintile 68,280 (19.3) 16.3 (16.1-16.6) 8.6 (8.4-8.9) 7.7 (7.5-7.9) 6.26 (5.96-6.57)
Third quintile 71,168 (20.1) 18.3 (18.0-18.6) 10.1 (9.8-10.3) 8.2 (8.0-8.4) 5.64 (5.36-5.94)
Fourth quintile 68,152 (19.3) 15.7 (15.4-16.0) 8.5 (8.3-8.7) 7.2 (7.0-7.3) 5.44 (5.17-5.73)
Fifth quintile (most
deprived)
63,022 (17.8) 16.4 (16.1-16.7) 9.1 (8.9-9.3) 7.3 (7.1-7.5) 4.50 (4.24-4.77)
*Defined as having any of the following conditions: endometriosis, polycystic ovary syndrome, menorrhagia, acne, metrorrhagia, bilateral salpingo-oophorectomy, hysterectomy
bilateral salpingo-oophorectomy, hysterectomy, fibroids, and menometrorrhagia.
The differences between groups of background variables were statistically significant (P < .001).
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gen and progestogen HRT was highest among women 51 to 55
years of age compared with that in other age groups; it was higher
in ex-smokers or current smokers than in nonsmokers (which was
a surprising finding), highest in those with a BMI less than 25 kg/
m2 versus in women with a higher BMI score, higher in women
who had never been pregnant versus in thosewith a recorded preg-
nancy; and lowest in women with a comorbidity score of 1 to 3
versus in those with fewer and or a greater number of comorbid-
ities, with no differences found between IMD quintiles. Although
use of any HRT was similar between premenopausal and post-
menopausal women, use of combined estrogen and progestogen
HRT was more common in perimenopausal women than inpostmenopausal women whereas use of estrogen-only HRT was
more common in postmenopausal than in perimenopausal
women. Use of any HRT and estrogen-only HRT was higher in
women with a prior gynecologic condition than in those without
such a condition, whereas the reverse was found for combined es-
trogen and progestogen HRT.
During the 17 years of follow-up (1,340,423 person years),
7,614 new asthma cases were observed, giving an incidence rate
of 5.7 cases (95% CI 5 5.5-5.8) per 1000 person years. The
incidence rate of asthma increased with increasing age; it was
similar between premenopausal and postmenopausal women,
higher in ex-smokers and current smokers than in nonsmokers,
increased with increasing BMI, decreased with increasing
FIG 2. Flowchart of the study cohort and baseline use of HRT.
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4 SHAH ET ALnumber of pregnancies, lower in women with prior gynecologic
conditions than in those without such a condition; similar across
the range of Charlson Comorbidity Index scores, and decreased
with increasing IMD quintiles (Table I).Associations of HRT and menopause with asthma
onset
Previous use of any HRT, estrogen-only HRT, and combined
estrogen and progestogen HRTwere associated with up to an 18%
(95% CI5 24-12) reduction in risk of development of new-onset
asthma when compared with the risk among women who did not
use HRT (Table II). Similarly, current use of any HRT, estrogen-
only HRT, and combined estrogen and progestogen HRT was
associated with up to a 22% (95% CI 5 30-13) reduced risk of
development of asthma than among those who did not use HRT.
We observed a dose-response association (Kandall t statistic 5
–1 [P 5 .089]) between duration of HRT use and risk of asthma
onset: women with 1 to 2 years of HRT use had a 7% (95%
CI5 13-1) lower risk than women who did not use HRT, women
with 3 or 4 years of use had a 23% lower risk (95% CI5 30-16),
and those with 5 or more years of use had a 29% (95% CI 5 36-
22) lower risk. Postmenopausal women, compared with perimen-
opausal women, had a 12% (95% CI 5 17-8) reduced risk of
asthma onset. Stratified by menopausal status, we found statisti-
cally significant associations only with current use of HRT and
its subtypes, and in these cases, the reduction in asthma onset
was slightly greater in perimenopausal than in postmenopausal
women (Table II). In analyses stratified by BMI and smoking,
we found statistically significant associations only with current
use of any HRT and it subtypes and asthma onset (most likely
because stratified analyses lacked sufficient power to detect sig-
nificant effect); however, the effect estimates were generally
similar across the categories of BMI and smoking (Table III).
Kaplan-Meier survival curves confirmed that the risk of remain-
ing asthma-free was lower in women who used HRT than in those
who did not use it (Fig 3, see Supplement 4 in the Online Repos-
itory at www.jacionline.org for Kaplan-Meier survival curve
stratified by menopausal status). Figs 4 and 5 summarize Tables
II and III, illustrating the hazard ratios obtained in a forest plot.The E-values for the association of use of any HRT, use of HRT
subtypes, and duration of use with asthma onset ranged from 1.36
(for the effect of 1-2 years of HRTuse) to 2.17 (for the effect of >_5
years of HRT use), signifying that an unmeasured confounder
would require a minimum effect measure of 1.36 and a maximum
of 2.17 beyond the adjusted confounders to negate the observed
risk estimates.DISCUSSION
Summary of key findings
Use of any HRT, estrogen-only HRT, or combined estrogen and
progestogen HRT, was associated with a decreased risk of
development of new-onset asthma among perimenopausal and
postmenopausal women. However, use of HRT was associated
with a reduced risk of asthma only in all women, but not when the
womenwere stratified bymenopausal status. Duration of HRTuse
was associated with a decreased risk of asthma onset in a dose-
response manner, so that women who used HRT for longer
periods had greater protection than did women who used it for
shorter periods. This effect becomes insignificant, however, when
patients are stratified by age, BMI, and smoking, possibly because
of lack of sufficient power to detect significant effect after
stratification. Compared with perimenopausal women, postmen-
opausal women were at lower risk of development of asthma.Strengths and limitations of the study
The key strengths of this studywere that thus far, it is the largest
longitudinal cohort study on the topic; it had a long follow-up
period (17 years); and it is based on a real-life, nationwide
primary care data set. With the large sample size, we were able to
investigate the associations between both subtypes and duration
of HRT use on the risk of asthma onset in different subgroups of
women (eg, subgroups based on smoking status and BMI) with
considerable precision. The OPCRD included longitudinal en-
counters of 6.3million well-characterized patients registeredwith
630 general practices from across the United Kingdom. This
database is representative of the United Kingdom–wide primary
care population; thus, findings have direct generalizability to the
wider UK population. The long-term follow-up meant that we
could study the longer-term impact of HRT on asthma onset.
This work used the Read coding system, which is a standard-
ized system for recording primary care diagnoses and clinical
encounters across the United Kingdom, to identify and define all
variables used in the study. On the basis of GP-recorded
parameters, as opposed to the self-administered subjective
assessments used in most previous studies,1,18-23 we had consis-
tent measurement of the study exposures, potential confounders,
and outcome. The longitudinal framework of the OPCRD data-
base enabled us to undertake time-dependent multilevel survival
analysis. In this type of analysis, instead of forcing us to define
participants as either users or nonusers of HRT throughout the
follow-up of the study, the time-dependent approach allowed us
to take account of the possibility that the status of participants
regarding use of HRT could change over the study period.
Thus, participants were counted as nonusers in the years during
which they did not use HRT and were counted as users only in
the years during which they used HRT. This approach meant
that we minimized immortal time bias, which is a common bias
TABLE II. Association between use of HRT and onset of asthma in all women and by menopausal status
HRT use
Asthma onset









Previous use of any HRT
None 1 1 1 1
Yes 0.82 (0.78-0.86) 0.83 (0.79-0.88) 0.84 (0.78-0.91) 0.86 (0.80-0.92)
Current use of any HRT
None 1 1 1 1
Yes 0.75 (0.70-0.80) 0.79 (0.74-0.85) 0.68 (0.61-0.75) 0.86 (0.79-0.95)
Type of HRT (previous
use)
None 1 1 1 1
Estrogen only 0.87 (0.82-0.93) 0.89 (0.84-0.95) 0.98 (0.88-1.08) 0.89 (0.82-0.97)
Combined estrogen 1
progestogen
0.82 (0.77-0.88) 0.82 (0.76-0.88) 0.78 (0.70-0.87) 0.88 (0.80-0.97)
Type of HRT (current
use)
None 1 1 1 1
Estrogen only 0.74 (0.68-0.81) 0.80 (0.73-0.87) 0.73 (0.64-0.83) 0.84 (0.74-0.94)
Combined estrogen 1
progestogen
0.76 (0.69-0.85) 0.78 (0.70-0.87) 0.61 (0.53-0.71) 0.93 (0.80-1.08)
Duration of use of any
HRT (y)
None 1 1 1 1
1-2 0.91 (0.86-0.97) 0.93 (0.87-0.99) 0.92 (0.83-1.01) 0.96 (0.87-1.05)
3-4 0.75 (0.69-0.82) 0.77 (0.70-0.84) 0.76 (0.66-0.88) 0.76 (0.68-0.85)





1 1 Not applicable Not applicable
Postmenopauseal (age
56-70 y)
0.91 (0.87-0.96) 0.88 (83-0.92)
All analysis were based on a multilevel Cox regression that accounted for clustering of patients within GP practices. Both unadjusted and adjusted models were adjusted for use of
HRT. Boldface indicates statistical significance.
*Adjusted for age, smoking, Charlson Comorbidity Index score, BMI, gravidity, any gynecologic condition, and IMD quintile.
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cal therapies on disease outcomes.24
The Quality and Outcomes Framework (QOF), a national
initiative and the first of its kind in the world that provided
incentives to encourage UK primary care to develop a register of
patients with asthma, came into existence in 2004.25 The QOF
included regular registry audits and consequently led to improve-
ment in a GPs’ recording of clinical events.26 Most of the follow-
up period in our study (13 of 17 years) was after adoption of the
QOF, thereby minimizing bias due to asthma underdiagnosis (see
Supplement 5 in the Online Repository at www.jacionline.org for
a sensitivity analysis that excluded all patients who joined the
study before the QOF was introduced). Furthermore, to ensure
that only at-risk women (ie, those who did not have asthma at
the start of follow-up) were included in the study, we used a
5-year look-back period under the assumption that women with
asthmawould have had at least 1 contact with primary care during
the 5 years preceding the start of follow-up. It is possible, howev-
er, that a minority of patients who despite being diagnosed with
asthma, had no primary care contact during the 5 years preceding
the start of follow-up and thus may have been incorrectly classi-
fied as asthma-free. The risk of confounding by indication was
minimized through identification of a comprehensive list ofconditions for which HRT is also used, and we adjusted for these
conditions in our analyses.
A potential limitation is that the menopausal status of females
was based only on the ages of women, which was the only
information available from the database for this purpose.
Nevertheless, the cutoff years we used to define perimenopausal
and postmenopausal women were based on the average age of
occurrence of these events in the United Kingdom. Furthermore,
we have assumed that any prescriptions of HRT were used
according to a GP’s prescription, which may not always be the
case. We were unable to adjust for ethnicity, as this information
was missing in more than 70% of cases. We had originally
planned to carry out propensity score matching analysis to reduce
the bias due to the confounding variables. We were, however,
unable to design an appropriate statistical model (given the time-
varying and multicategoric nature of the study exposures within
multilevel models), and therefore, we performed a conventional
confounding adjustment. It is possible that some residual
confounding has remained even after controlling for various
confounders; however, our evaluation of unmeasured con-
founders indicates that this may be an unlikely explanation for
our findings. Furthermore, our original protocol contained an
analysis that included the route of HRT administration (oral,
TABLE III. Association between use of HRT and onset of asthma in menopausal women and by BMI and smoking
HRT use by BMI
Asthma onset
Stratified analyses by BMI, hazard ratio (95% CI)*,y
Stratified analyses by smoking status,
hazard ratio (95% CI)*,z
<25 kg/m2 25-29.9 kg/m2 >_30 kg/m2 Nonsmokers Smokers
Previous use of any HRT
None 1 1 1 1 1
Yes 0.98 (0.88-1.08) 0.94 (0.86-1.02) 0.99 (0.91-1.08) 1.01 (0.94-1.10) 0.94 (0.87-1.01)
Current use of any HRT
None 1 1 1 1 1
Yes 0.76 (0.67-0.87) 0.72 (0.64-0.81) 0.72 (0.63-0.81) 0.75 (0.67-0.83) 0.72 (0.66-0.80)
Type of HRT (previous use)
None 1 1 1 1 1
Estrogen only 1.02 (0.91-1.15) 1.03 (0.93-1.15) 1.00 (0.90-1.11) 1.07 (0.97-1.18) 0.99 (0.90-1.06)
Combined estrogen 1 progestogen 0.99 (0.86-1.15) 0.85 (0.76-0.96) 1.00 (0.88-1.12) 1.00 (0.89-1.13) 0.91 (0.82-1.00)
Type of HRT (current use)
None 1 1 1 1 1
Estrogen only 0.79 (0.68-0.93) 0.78 (0.67-0.90) 0.70 (0.60-0.82) 0.74 (0.65-0.85) 0.76 (0.67-0.87)
Combined estrogen 1 progestogen 0.73 (0.59-0.90) 0.64 (0.53-0.77) 0.74 (0.62-0.90) 0.76 (0.63-0.91) 0.67 (0.59-0.76)
Duration of use of any HRT, y
None 1 1 1 1 1
1-2 1.00 (0.89-1.13) 0.90 (0.80-1.00) 0.96 (0.86-1.08) 1.01 (0.91-1.12) 0.91 (0.83-1.00)
3-4 0.86 (0.72-1.03) 0.91 (0.78-1.05) 0.98 (0.85-1.14) 0.99 (0.86-1.15) 0.88 (0.78-0.99)
>_ 5 1.04 (0.86-1.25) 1.12 (0.95-1.32) 1.08 (0.92-1.26) 1.04 (0.88-1.23) 1.10 (0.97-1.24)
Perimenopausal (age 46-55 y)§ 1 1 1 1 1
Postmenopausal (age 56-70 y)§ 0.98 (0.88-1.10) 1.05 (0.95-1.15) 1.01 (0.93-1.10) 1.02 (0.94-1.11) 1.02 (0.94-1.10)
All analysis were based on a multilevel Cox regression that accounted for clustering of patients within GP practices. Boldface indicates statistical significance.
*Adjusted for age, smoking, Charlson Comorbidity Index score, BMI, gravidity, any gynecologic condition, and IMD quintile.
Stratified analyses performed after interaction term between use of HRT and BMI gave P < .20.
Stratified analyses performed after interaction term between use of HRT and smoking gave P < .20.
§Menopausal status at baseline.
FIG 3. Kaplan-Meier curves comparing current users and nonusers of HRT among menopausal women. A,
Difference in risk of remaining free of asthma between users and nonusers of any HRT. B. Comparison of the
risk of remaining free of asthma by type of HRT.
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FIG 4. Association between use of HRT and onset of asthma in all women.
FIG 5. Association between use of HRT and onset of asthma by menopausal status.
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However, after the data had been acquired, this information was
found to be inconsistently recorded in the database, and therefore
we did not proceed with this analysis.
Lastly, although we defined asthma onset on the basis of GP-
recorded diagnosis, it is possible that some of these cases might be
a misdiagnosis for chronic obstructive pulmonary disease. How-
ever, given that the Read codes for asthma diagnosis have been
validated previously in a comparable database with high accu-
racy27 and the concomitance of asthma and chronic obstructive
pulmonary disease based on Read codes is less than 15%,28 we
believe such cases to be minimal if present and unlikely to change
our conclusions.Comparison of findings with previous literature
Although some previous studies have generally shown an
increased risk of asthma onset with the use of HRT,15,18-23 con-
trary findings have also been reported.1-3,29-31 Most previous
studies were cross-sectional.21-23 Three studies identified in our
systematic review were prospective cohort studies.1,18-20 The
Nurses’ Health Study18,20 reported that previous and current use
of HRT and subtypes, including HRT use for more than 10 years
but not a shorter duration of use, were associated with an
increased risk of new-onset asthma in postmenopausal women.
The French E3N cohort study found a statistically significant
increased risk of new-onset asthma with use of estrogen-only
HRT, but not with use of combined estrogen and progestogen
J ALLERGY CLIN IMMUNOL
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or duration of usewith risk of asthma in postmenopausal women.1
Another prospective cohort study found that use of anyHRT, HRT
subtypes, and long duration of use were associated with increased
risk of new-onset asthma.19 The findings are in contrast to the
findings in our study, in which we showed that current HRT
use, its subtypes, and long duration of use were associated with
a decreased risk of new-onset asthma. Whereas the previous
cohort studies included only postmenopausal women, our study
included both perimenopausal and postmenopausal women; yet
our findings were similar in both perimenopausal and postmeno-
pausal women when analyzed separately. The assessment of HRT
and/or asthma was based on subjective self-reported question-
naires in previous studies, giving a potential for information
and recall bias. Our study, apart from being the largest longitudi-
nal cohort study on the topic to date, used real-life primary care
records (ie, records maintained for the purpose of routine care)
based on GP-recorded HRT prescription and asthma diagnosis.
Only 2 previous cohort studies used HRT as a time-dependent
exposure, but even in those studies, information on HRT use
from biennial surveys was updated only every 2 years.1,18,20 In
our study, we were able to update information on HRT use yearly
throughout the follow-up period (from the prescribing record),
which then provides more precise information on HRT. Similar
to our findings, results from the Nurses’ Health Study showed
that postmenopausal women were at a lower risk of development
of asthma than perimenopausal women were.20 When partici-
pants were stratified by smoking status, the French E3N study
found that risk was specific to nonsmokers only.1 Our results,
however, showed similar risks among smokers and nonsmokers
and across the categories of BMI.Interpretation and possible mechanisms of action
HRT is proposed to exert both anti-inflammatory and proin-
flammatory effects on innate32,33 and adaptive immune path-
ways,34 highlighting a potentially complex role in asthma
pathogenesis. The estrogen receptors (ERs), ERa and ERb, are
widely expressed on immune cells, and both are present in the
lung.32,35 Estrogen signaling appears context and dose dependent.
For example, ERa has been shown to promote proinflammatory
cytokine synthesis in response to Toll-like receptor ligation in
dendritic cells and macrophages, whereas higher levels may pro-
mote anti-inflammatory responses.33 An imbalance of ERa and
ERb expression has been reported in the airways of individuals
with asthma versus in healthy airways36 that may also influence
the nature of responses. Recent reports describe differential ef-
fects of signaling via ERa and ERb, with signaling of airway
smooth muscle cells via ERb being protective. This included
regulation of airway smooth muscle cell contractility to relax air-
ways35 and downregulation of AHR and airway remodeling by
ERb signaling.37 Elegant studies comparing intranasal allergen
challenge in wild-type, ERa knockout mice, and ERb knockout
mice demonstrate exacerbated airway hyperresponsiveness, im-
mune cell infiltration, and remodeling in ERb knockout mice,
which were most prominent in female mice.38
Several studies have demonstrated that both progesterone and
estrogen increase regulatory T–cell frequency and/or function,
which is predicted to contribute to protective effects of HRT and
beneficially affect asthma outcomes.34 In contrast, estrogen and
progesterone have been variously reported to inhibit and enhanceTH1, TH2, and TH17 effector cell responses.
34,39-41 These studies
highlight the complexity of sex hormone effects on structural,
innate, and adaptive immune cells, as well as the influence of
an inflammatory milieu, receptor signaling, and hormone concen-
tration. The findings from the current study, which contrast those
of 3 cohort studies described earlier, provide strong evidence
demonstrating that use of HRT and its subtypes previously,
currently, and long-term is associated with a clinically significant
reduced risk of development of asthma in menopausal women.
Whether these contradictory findings are the result of complex
roles of HRT is unclear. Perhaps, they indicate the presence of a
number of mechanisms by which HRT can influence asthma out-
comes, and they highlight the need for further detailed and longi-
tudinal mechanistic studies alongside observational studies.Conclusion
Our study found that past use and current use of HRT and its
subtypes are associated with a reduced risk of development of
new-onset asthma in menopausal women. Further prospective
cohort studies are now required to confirm these findings. There is
also a need for mechanistic studies to elucidate the specific
pathways through which HRT may influence inflammation lead-
ing to asthma pathogenesis.
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Key messages
d Our national, longitudinal study found that HRT is associ-
ated with reduced risk of clinically important reductions
in the development of asthma in menopausal women.
d These findings now need to be validated in other popula-
tions, and there is also the need for mechanistic studies to
investigate the possible protective role of menopausal hor-
mone therapy in the pathogenesis of asthma in women.REFERENCES
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